Collagen I enhances functional activities of human monocyte-derived dendritic cells via discoidin domain receptor 2

Cellular Immunology

Volumn 278, Issue 1-2, 2012, Pages 95-102

  Poudel, Barun ^a   Yoon, Dong Sik ^a   Lee, Jeong Heon ^a   Lee, Young Mi ^b   Kim, Dae Ki ^a  

^a Chonbuk National University Medical School   (South Korea)

^b Wonkwang University   (South Korea)

Author keywords

Collagen; Discoidin domain receptors; Human monocyte derived dendritic cells; Interleukin 12; Maturation; Melanoma

Indexed keywords

COLLAGEN TYPE 1; DENDRITIC CELL VACCINE; DISCOIDIN; DISCOIDIN DOMAIN RECEPTOR 1; DISCOIDIN DOMAIN RECEPTOR 2; GAMMA INTERFERON; INTERLEUKIN 12P40; RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; CANCER SURVIVAL; CELL ACTIVITY; CELL FUNCTION; CYTOKINE RELEASE; DENDRITIC CELL; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MELANOMA; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; SURVIVAL TIME; TUMOR VOLUME;

ANIMALS; CANCER VACCINES; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; COLLAGEN TYPE I; DENDRITIC CELLS; FEMALE; GENE EXPRESSION; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-12 SUBUNIT P40; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MONOCYTES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, MITOGEN; RNA, SMALL INTERFERING; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

MUS;

EID: 84868276243     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2012.07.004     Document Type: Article

References (42)

1. Steinman R.M., Cohn Z.A. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J. Exp. Med. 1973, 137:1142-1162.
2. Steinman R.M., Witmer M.D. Lymphoid dendritic cells are potent stimulators of the primary mixed leukocyte reaction in mice. Proc. Natl. Acad. Sci. 1978, 75:5132-5136.
3. Nussenzweig M.C., Steinman R.M., Gutchinov B., Cohn Z.A. Dendritic cells are accessory cells for the development of anti-trinitrophenyl cytotoxic lymphocytes. J. Exp. Med. 1980, 152:1070-1084.
4. Steinman R.M. Dendritic cells: understanding immunogenicity. Eur. J. Immunol. 2007, 37:53S-60S.
5. Ueno H., Klechevsky E., Morita R., Aspord C., Cao T., Matsui T., Pucchio T.D., Connolly J., Fay J.W., Pascual V., Palucka A.K., Banchereau J. Dendritic cell subsets in health and disease. Immunol. Rev. 2007, 219:118-142.
6. Fearnley D.B., McLellan A.D., Mannering S.I., Hock B.D., Hart D.N.J. Isolation of human blood dendritic cells using the CMRF-44 monoclonal antibody: implications for studies on antigen-presenting cell function and immunotherapy. Blood 1997, 89:3708-3716.
7. Lanzavecchia A., Sallusto F. Regulation of T cell immunity by dendritic cells. Cell 2001, 106:263-266.
8. Kapsenberg M.L. Dendritic-cell control of pathogen-driven T-cell polarization. Nat. Rev. Immunol. 2003, 3:984-993.
9. Ebnet K., Kaldjian E.P., Anderson A.O., Shaw S. Orchestrated information transfer underlying leukocyte endothelial interactions. Annu. Rev. Immunol. 1996, 14:155-177.
10. Gretz J.E., Kaldjian E.P., Anderson A.O., Shaw S. Sophisticated strategies for information encounter in the lymph node: the reticular network as a conduit of soluble information and a highway for cell traffic. J. Immunol. 1996, 157:495-499.
11. Mahnke K., Bhardwaj R.S., Luger T.A., Schwarz T., Grabbe S. Interaction of murine dendritic cells with collagen up-regulates allostimulatory capacity, surface expression of heat stable antigen, and release of cytokines. J. Leukoc. Biol. 1996, 60:465-472.
12. Carlos T., Harlan J. Leukocyte-endothelial adhesion molecules. Blood 1994, 84:2068-2101.
13. Staquet M.J., Kobayashi Y., Dezutter D.C., Schmitt D. Role of specific successive contacts between extracellular matrix proteins and epidermal Langerhans cells in the control of their direct migration. Eur. J. Cell Biol. 1995, 66:342-348.
14. Hynes R. Integrins: versatility, modulation and signaling in cell adhesion. Cell 1992, 69:11.
15. Suri R.M., Austyn J.M. Bacterial lipopolysaccharide contamination of commercial collagen preparations may mediate dendritic cell maturation in culture. J. Immunol. Methods 1998, 214:149-163.
16. Valiathan R.R., Marco M., Leitinger B., Kleer C.G., Fridman R. Discoidin domain receptor tyrosine kinases: new players in cancer progression. Cancer Metastasis Rev. 2012, 31:295-321.
17. Alves F., Vogel W., Mossie K., Millauer B., Hofler H., Ullrich A. Distinct structural characteristics of discoidin I subfamily receptor tyrosine kinases and complementary expression in human cancer. Oncogene 1995, 10:609-618.
18. Hou G., Vogel W.F., Bendeck M.P. Tyrosine kinase activity of discoidin domain receptor 1 is necessary for smooth muscle cell migration and matrix metalloproteinase expression. Circ. Res. 2002, 90:1147-1149.
19. Vogel W., Gish G.D., Alves F., Pawson T. The discoidin domain receptor tyrosine kinases are activated by collagen. Mol. Cell 1997, 1:13-23.
20. Lee J.E., Kang C.S., Guan X.Y., Kim B.T., Kim S.H., Lee Y.M., Moon W.S., Kim D.K. Discoidin domain receptor 2 is involved in the activation of bone marrow-derived dendritic cells caused by type I collagen. Biochem. Biophys. Res. Commun. 2007, 352:244-250.
21. Ruiz P.A., Jarai G. Collagen I induces discoidin domain receptor (DDR) 1 expression through DDR2 and a JAK2-REK1/2-mediated mechanism in primary human lung fibroblasts. J. Biol. Chem. 2011, 286:12912-12923.
22. Ford C.E., Lau S.K., Zhu C.Q., Andersson T., Tsao M.S., Vogel W.F. Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma. Br. J. Cancer 2007, 96:808-814.
23. Zheng Z., Takahashi M., Narita M., Toba K., Liu A., Furukawa T., Koike T., Aizawa Y. Generation of dendritic cells from adherent cells of cord blood by culture with granulocyte-macrophage colony stimulating factor, interleukin-4, and tumor necrosis factor-alpha. J. Hematother. Stem Cell Res. 2000, 9:453-464.
24. Vogel W., Brakebusch C., Fassler R., Alves F., Ruggiero F., Pawson T. Discoidin domain receptor 1 is activated independently of beta(1) integrin. J. Biol. Chem. 2000, 275:5779-5784.
25. Roake J.A., Rao A.S., Morris P.J., Larsen C.P., Hankins D.F., Austyn J.M. Dendritic cell loss from nonlymphoid tissues after systemic administration of lipopolysaccharide, tumor necrosis factor, and interleukin 1. J. Exp. Med. 1995, 181:2237-2247.
26. Bros M., Jährling F., Renzing A., Wiechmann N., Dang N.A., Sutter A., Ross R., Knop J., Sudowe S., Reske-Kunz A.B. A newly established murine immature dendritic cell line can be differentiated into a mature state, but exerts tolerogenic function upon maturation in the presence of glucocorticoid. Blood 2007, 109:3820-3829.
27. Radymayr C., Bock G., Hobisch A., Klocker H., Bartsch G., Thurnher M. Dendritic antigen-presenting cells from the peripheral blood of renal-cell-carcinoma patients. Int. J. Cancer 1995, 63:627-632.
28. Zhou L.J., Tedder T.F. Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. J. Immunol. 1995, 154:3821-3835.
29. Sansom D.M., Manzotti C.N., Zheng Y. What's the difference between CD80 and CD86?. Trends Immunol. 2003, 24:314-319.
30. Hsu F.J., Benike C., Fagnoni F., Liles T.M., Czerwinski D., Taidi B., Engleman E.G., Levy R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 1996, 2:52-58.
31. Timmerman J.M., Czerwinski D.K., Davis T.A., Hsu F.J., Benike C., Hao Z.M., Taidi B., Rajapaksa R., Caspar C.B., Okada C.Y., van Beckhoven A., Liles T.M., Engleman E.G., Levy R. Idiotype pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002, 99:1517-1526.
32. Tsuda K., Yamanaka K., Linan W., Miyahara Y., Akeda T., Nakanishi T., Kitagawa H., Kakeda M., Kurokawa I., Shiku H., Gabazza E.C., Mizutani H. Intratumoral injection of Propionibacterium acnes suppresses malignant melanoma by enhancing Th1 immune responses. PLoS ONE 2011, 6:e29020.
33. Bear A.S., Cruz C.R., Foster A.E. T cells as vehicles for cancer vaccination. J. Biomed. Biotechnol. 2011, 2011:1-7.
34. Banchereau J., Palucka A.K. Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol. 2005, 5:296-306.
35. Klebanoff C.A., Acquavella N., Yu Z., Restifo N.P. Therapeutic cancer vaccines: are we there yet?. Immunol. Rev. 2011, 239:27-44.
36. Rosenberg S.A., Yang J.C., Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 2004, 10:909-915.
37. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 2003, 3:133-146.
38. Idzko M., Panther E., Stratz C., Müller T., Bayer H., Zissel G., Dürk T., Sorichter S., Di Virgilio F., Geissler M., Fiebich B., Herouy Y., Elsner P., Norgauer J., Ferrari D. The serotoninergic receptors of human dendritic cells: indentification and coupling to cytokine release. J. Immunol. 2004, 172:6011-6019.
39. Franco C.D., Hou G., Bendeck M.P. Collagens, integrins, and the discoidin domain receptors in arterial occlusive disease. Trends Cardiovasc. Med. 2002, 12:143-148.
40. Page-McCaw A., Ewald A.J., Werb Z. Matrix metalloproteinases and the regulation of tissue remodeling. Nat. Rev. Mol. Cell Biol. 2007, 8:221-233.
41. Olaso E., Lin H.C., Wang L.H., Friedman S.L. Impaired dermal wound healing in discoidin domain receptor 2-deficient mice associated with defective extracellular matrix remodeling. Fibrogenesis Tissue Repair 2011, 4:1-9.
42. Chabot V., Reverdiau P., Iochmann S., Rico A., Senecal D., Foupille C., Sizaret P.Y., Sensebe L. CCL5-enhanced human immature dendritic cell migration through the basement membrane in vitro depends on matrix metalloproteinase-9. J. Leukoc. Biol. 2006, 79:767-778.